Department of Rheumatology, CHU Nantes, 1 place Alexis Ricordeau, 44000, Nantes, France.
Department of Nuclear Medicine, CHU Nantes, Nantes, France.
Arthritis Res Ther. 2020 Nov 18;22(1):272. doi: 10.1186/s13075-020-02318-5.
To report on the characteristics and long-term course of rheumatic manifestations in Schnitzler syndrome (SchS).
A retrospective cohort study of patients with SchS followed between 2000 and 2020. Inclusion criteria included a diagnosis of SchS (Strasbourg criteria). All available bone scans were reviewed and scored according to the intensity and number of pathological sites. The scintigraphic score was compared with the clinical activity score, CRP level, and treatments.
Twenty-five patients were included. Median age at diagnosis was 68 years. Eighty patients (72%) had SchS-related rheumatic pain. Most patients had a long-standing isolated rash before constitutional and/or rheumatic symptoms appeared. The monoclonal component level was usually very low (IgMκ in 22/25). Rheumatic pain predominated around the knees. Bone scans revealed abnormal tracer uptake in 15/18 (85%). The scintigraphic score correlated with clinical activity (r = 0.4, p < 0.02) and CRP level (r = 0.47, p < 0.01). The scintigraphic score was lower in patients receiving corticosteroids or IL1Ra (interleukin 1 receptor antagonist) than in untreated patients (median scores:2, 0, and 13, respectively; p < 0.05). Two patients developed Waldenström macroglobulinemia. Of the 22 surviving patients, median age at follow-up was 76 years. IL1Ra was used in 13 patients, with dramatic efficacy on both symptoms and bone scan features.
Rheumatic manifestations are very prevalent in SchS. However, bone pain can be misleading and contribute to misdiagnosis. Bone scan abnormalities are very prevalent and correlate with disease activity and treatments. IL1-Ra has a dramatic and durable efficacy but may not be required in every patient early on.
报告 Schnitzler 综合征(SchS)患者的风湿表现特征和长期病程。
对 2000 年至 2020 年间随访的 SchS 患者进行回顾性队列研究。纳入标准包括 SchS 诊断(Strasbourg 标准)。回顾所有可获得的骨扫描结果,并根据病理部位的强度和数量进行评分。将闪烁扫描评分与临床活动评分、CRP 水平和治疗方法进行比较。
共纳入 25 例患者,诊断时的中位年龄为 68 岁。80 例(72%)患者有 SchS 相关的风湿痛。大多数患者在出现全身症状和/或风湿症状之前,有长期孤立性皮疹。单克隆成分水平通常非常低(25 例中有 22 例为 IgMκ)。风湿痛主要累及膝关节。骨扫描显示 18 例中有 15 例(85%)存在异常示踪剂摄取。闪烁扫描评分与临床活动(r=0.4,p<0.02)和 CRP 水平(r=0.47,p<0.01)相关。接受皮质类固醇或 IL1Ra(白细胞介素 1 受体拮抗剂)治疗的患者闪烁扫描评分低于未接受治疗的患者(中位数分别为 2、0 和 13;p<0.05)。有 2 例患者发展为 Waldenström 巨球蛋白血症。在 22 例存活患者中,中位随访年龄为 76 岁。13 例患者使用 IL1Ra,其对症状和骨扫描特征均有显著疗效。
风湿表现非常常见于 SchS。然而,骨痛可能会造成误导,导致误诊。骨扫描异常非常常见,与疾病活动度和治疗方法相关。IL1-Ra 具有显著且持久的疗效,但并非每个患者早期都需要使用。